Medicare overspending on anemia drug
The U.S. health-care system is vastly overspending for a single anemia drug because Medicare overestimates its use by hundreds of millions of dollars a year, according to an analysis of federal data. The overpayment to hospitals and clinics arises because Medicare reimburses them based on estimates rather than the actual use of the drug.
- Patient Harm Data to Remain on Medicare's Hospital Compare Site
- CMS Seeks to 'Rapidly Reduce' Medicare Spending with $1B in Grants
- Hard-Nosed About Physician Teamwork
- Quiet ORs Better for Patient Safety
- Building a Better Healthcare Board
- Case Study: Advance Care Conversations
- Tavenner Confirmed as CMS Administrator
- CMS Releases Hospital Pricing Data
- Access to EHR Notes Lauded by Patients, Providers
- Leapfrog Hospital Safety Scores 'Depressing'